Forging a New Future
Mallinckrodt and Endo have united to better serve customers and deliver hope to patients.
Uniting to Unlock Growth
From the union of Mallinckrodt and Endo, we intend to establish two new industry leaders that provide patients with therapeutics designed to improve life.
Our plan for the future is bold. In the months ahead, we will work to create from the combined entity two focused companies—a branded pharmaceuticals business, and a broad-based generics and sterile injectables business, which will be called Par Health.
Above all, we aim to enhance life for patients seeking high-quality treatments, assist healthcare providers striving to provide exceptional care, and deliver results for everyone who relies on us.
Combining Our Strengths
Serving Diverse Patient Needs
We are well-positioned to expand our business across a range of underserved therapeutic areas, including immunology, urology, orthopedics, endocrinology, and rare disease, as well as generic and sterile injectable medications and hospital-based care.
Scaled for Greater Impact
We will serve more patients in moments of need, with dedicated operations, deep expertise, and an unmatched commitment to excellence across two focused businesses.
Robust Manufacturing Capabilities
Our global infrastructure network includes 17 manufacturing sites—with 30 distribution centers—supporting vertical integration, secure supply, and consistent product quality at scale.
Meaningful Financial Flexibility
With a strong financial profile, we have the flexibility to invest in promising innovations and business development opportunities to drive growth.
Meet Our Leadership Team
Our leadership team includes seasoned professionals with a deep commitment to improving the lives of patients.